SCHEMBL24312083

SCHEMBL24312083

CSc1nc(C)c(C)cc1C(F)(F)F

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.38
KDM4E B2RXH2 2/20 0.38
L3MBTL1 Q9Y468 2/20 0.38
TDP1 Q9NUW8 1/20 0.38
LRRK2 Q5S007 1/20 0.35
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
HPGD P15428 2/20 0.35
NPSR1 Q6W5P4 1/20 0.35
SORT1 Q99523 1/20 0.33
HSP90AB1 P08238 1/20 0.33
GABRP O00591 6/20 0.33
GABRD O14764 6/20 0.33
GABRA1 P14867 6/20 0.33
GABRB1 P18505 6/20 0.33
GABRG2 P18507 6/20 0.33
GABRB3 P28472 6/20 0.33
GABRA5 P31644 6/20 0.33
GABRA3 P34903 6/20 0.33
GABRA2 P47869 6/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24312322 0.74 CFTR (0.39) ALDH1A1L3MBTL1LRRK2HPGDSORT1
SCHEMBL31027305 0.73 CFTR (0.45) ALDH1A1KDM4EKMT2AHPGDSORT1
SCHEMBL21956733 0.73 CFTR (0.45) ALDH1A1KDM4EKMT2AHPGDSORT1
SCHEMBL21956967 0.73 AR (0.35) LRRK2SORT1AR
SCHEMBL31018120 0.73 AR (0.35) LRRK2SORT1AR
SCHEMBL3047051 0.73 GABRP (0.37) ALDH1A1KDM4EL3MBTL1TDP1MEN1
SCHEMBL23942638 0.72 SORT1 (0.33) ALDH1A1KDM4EL3MBTL1HPGDSORT1
SCHEMBL38664495 0.71 TSHR (0.37) ALDH1A1KDM4EL3MBTL1MEN1KMT2A
SCHEMBL22016865 0.71 SORT1 (0.33) LRRK2HPGDSORT1HSD17B10
SCHEMBL10293004 0.67 PGK1 (0.41) ALDH1A1KDM4EMEN1KMT2AHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220152014-A1 COMPOUNDS FOR INHIBITION OF ALPHA 4 BETA 7 INTEGRIN GILEAD SCIENCES, INC. (US) 2022-05-19 US disclosed
US-20220119383-A1 QUINOLINE DERIVATIVES AS ALPHA4BETA7 INTEGRIN INHIBITORS GILEAD SCIENCES, INC. 2022-04-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220119383-A1 QUINOLINE DERIVATIVES AS ALPHA4BETA7 INTEGRIN INHIBITORS ITGB7, ITGB1, ITGA2B ALDH1A1 838/4885KDM4E 1390/4885L3MBTL1 4535/4885
US-20220152014-A1 COMPOUNDS FOR INHIBITION OF ALPHA 4 BETA 7 INTEGRIN ITGB7, ITGB4, ITGA4 ALDH1A1 823/4885KDM4E 1442/4885L3MBTL1 4194/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.